Skip to content
Research/Hormone Optimization/Progesterone (Bioidentical)

Progesterone (Bioidentical)

Prometrium, Crinone. Bioidentical form of endogenous progesterone. FDA-approved oral micronized Prometrium. Used in HRT for women, hormone balance, and sleep improvement.

Intelligence Profile

Clinical Applications

Bioidentical progesterone is primarily used in hormone replacement therapy (HRT) for menopausal women, typically in combination with estrogen. The available evidence focuses mainly on its role in comprehensive hormone therapy rather than as a standalone treatment.

Menopausal Hormone Therapy

The primary clinical application for bioidentical progesterone is as part of menopausal hormone therapy, where it is combined with estradiol to provide comprehensive hormonal support. Studies examining patterns of hormone therapy dispensing show that micronized progesterone is commonly prescribed alongside estrogen preparations for menopausal women. The combination approach aims to address both estrogen deficiency symptoms while providing endometrial protection.

Hormone Replacement Formulations

Clinical research has evaluated bioidentical progesterone in various formulations, including compounded preparations. A completed Phase 1 pharmacokinetic study (NCT00864214) examined bioidentical compounded estrogen cream combined with natural progesterone, though specific efficacy outcomes from this trial are not detailed in the available evidence.

Safety Considerations in Pregnancy

While not its primary indication, research has examined progesterone's safety profile in early pregnancy. A systematic review and meta-analysis found no additional risk of congenital anomalies after first-trimester dydrogesterone use, though this relates to synthetic progesterone rather than bioidentical forms specifically.

Evidence Limitations

The clinical evidence for bioidentical progesterone is somewhat limited. Two relevant clinical trials have incomplete or unknown status: a Phase 4 "Physiologic Restoration Study" (NCT04190927) with unknown completion status, and a Phase 2 study in early menopause (NCT00302731) that was terminated. This limits the availability of robust clinical trial data specifically for bioidentical progesterone formulations.

The existing literature primarily consists of narrative reviews and position papers rather than controlled clinical trials, which may limit the strength of evidence for specific clinical applications.

Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider for personalized treatment recommendations.

Free account required

Clinical data requires a free AXIFI account to access clinical data, safety profiles, and research papers.